![Olivier-Michielin](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/video/new-insights-into-the-use-of-liquid-biopsy-for-early-detection/8738212-3-eng-GB/new-insights-into-the-use-of-liquid-biopsy-for-early-detection_i770.png)
![Olivier-Michielin](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/video/new-insights-into-the-use-of-liquid-biopsy-for-early-detection/8738212-3-eng-GB/new-insights-into-the-use-of-liquid-biopsy-for-early-detection_i770.png)
![ESMO 2019 Barcelona](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/anlotinib-improves-overall-survival-in-relapsed-sclc/8734489-3-eng-GB/anlotinib-improves-overall-survival-in-relapsed-sclc_i770.jpg)
Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer
![ESMO-2019 view](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/cediranib-olaparib-combination-is-effective-regardless-of-disease-mutations/8734558-3-eng-GB/cediranib-olaparib-combination-is-effective-regardless-of-disease-mutations_i770.jpg)
Cediranib–olaparib combination is effective regardless of disease mutations
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer
![ESMO-2019 view](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/not-just-for-girls-so-who-else-should-be-vaccinated-for-hpv/8734903-3-eng-GB/not-just-for-girls-so-who-else-should-be-vaccinated-for-hpv_i770.jpg)
Not just for girls, so who else should be vaccinated for HPV?
Extending an HPV vaccination programme to include boys aged 12–14 years could help reduce the incidence of these infections
![ESMO Congress 2019](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/8733931-4-eng-GB/esmo-congress-2019.png)
A potential new targeted treatment for Notch mutation-positive tumours
A growing body of evidence has identified Notch mutations as a potential target in adenoid cystic carcinoma (ACC), a rare type of salivary gland carcinoma
![ESMO 2019-Tumour mutational burden_NSCLC|ESMO 2019-Tumour mutational burden_NSCLC](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/is-tissue-tumour-mutational-burden-a-predictive-biomarker-for-immunotherapy-in-lung-cancer/8735248-3-eng-GB/is-tissue-tumour-mutational-burden-a-predictive-biomarker-for-immunotherapy-in-lung-cancer_i770.jpg)
Is tissue tumour mutational burden a predictive biomarker for immunotherapy in lung cancer?
Two post-hoc analyses of KEYNOTE studies presented at ESMO 2019
![ESMO 2019_FGFR_cholangiocarcinoma](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/precision-medicine-bursts-onto-the-biliary-tract-cancer-scene/8735317-3-eng-GB/precision-medicine-bursts-onto-the-biliary-tract-cancer-scene_i770.jpg)
Precision medicine bursts onto the biliary tract cancer scene
The management of biliary tract cancers, especially cholangiocarcinoma, is rapidly changing with emerging new precision medicine strategies